Distinguished in Melanoma

Dr. Amita Patnaik

Oncology
South Texas Oncology And Hematology, PLLC
4383 Medical Dr, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Distinguished in Melanoma
South Texas Oncology And Hematology, PLLC
4383 Medical Dr, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amita Patnaik is an Oncologist in San Antonio, Texas. Dr. Patnaik is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Adenoid Cystic Carcinoma, Melanoma, Breast Cancer, and Non-Small Cell Lung Cancer (NSCLC). Dr. Patnaik is currently accepting new patients.

Her clinical research consists of co-authoring 96 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 10 articles and participated in 3 clinical trials in the study of Melanoma.

Specialties
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Methodist Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC
4383 Medical Dr, San Antonio, TX 78229
Other Locations
SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC
155 E Sonterra Blvd, Suite 200, San Antonio, TX 78258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 09, 2025
Intervention Type: Drug
Study Drug: SGN-B6A
Study Phase: Phase 1
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drug: SGN-PDL1V
Study Phase: Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: SGN-B7H4V
Study Phase: Phase 1
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Drug, Combination product
Study Phase: Phase 1
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
Study Phase: Phase 1
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drug: HER2/41BB Bispecific
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: SGN-CD228A
Study Phase: Phase 1
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: June 22, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Study of FCN-437c in Patients With Advanced Solid Tumors
Phase 1 Study of FCN-437c in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
Enrollment Status: Completed
Publish Date: March 01, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
Enrollment Status: Unknown
Publish Date: February 01, 2021
Intervention Type: Drug
Study Drug: Pyrotinib
Study Phase: Phase 1
A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Enrollment Status: Completed
Publish Date: October 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies
An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies
Enrollment Status: Terminated
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer
A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: April 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 22 Less Clinical Trials

96 Total Publications

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.
Journal: Targeted oncology
Published: February 03, 2025
Similar Doctors
Elite in Melanoma
Dr. Montaser F. Shaheen
Hematology | Hematology Oncology | Oncology
Elite in Melanoma
Dr. Montaser F. Shaheen
Hematology | Hematology Oncology | Oncology

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (0.4 miles away)
210-450-9000
Languages Spoken:
English, Arabic, Faroese, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Montaser Shaheen is a Hematologist and a Hematologist Oncology provider in San Antonio, Texas. Dr. Shaheen is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Neuroendocrine Tumor, Adult Soft Tissue Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Shaheen is currently accepting new patients.

Distinguished in Melanoma
Dr. Rebecca E. Barrington
Oncology | Hematology Oncology
Distinguished in Melanoma
Dr. Rebecca E. Barrington
Oncology | Hematology Oncology

Texas Oncology PA

694 Hill Country Dr, 
Kerrville, TX 
 (50.5 miles away)
830-792-3434
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Barrington is an Oncologist and a Hematologist Oncology provider in Kerrville, Texas. Dr. Barrington is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Paget Disease of the Breast, Large-Cell Immunoblastic Lymphoma, Colorectal Cancer, and Childhood Iron Deficiency Anemia. Dr. Barrington is currently accepting new patients.

Advanced in Melanoma
Dr. Kyriakos P. Papadopoulos
Hematology Oncology | Hematology | Oncology
Advanced in Melanoma
Dr. Kyriakos P. Papadopoulos
Hematology Oncology | Hematology | Oncology

South Texas Oncology And Hematology, PLLC

4383 Medical Dr, 
San Antonio, TX 
 (0.1 miles away)
210-593-5700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kyriakos Papadopoulos is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Papadopoulos is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Adenoid Cystic Carcinoma, Salivary Gland Tumors, Acute Megakaryoblastic Leukemia, and Breast Cancer. Dr. Papadopoulos is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patnaik's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile